Advertisement
U.S. markets open in 2 hours 7 minutes

BriaCell Therapeutics Corp. (BCT.TO)

Toronto - Toronto Real Time Price. Currency in CAD
0.9400-0.0700 (-6.93%)
At close: 03:59PM EST

BriaCell Therapeutics Corp.

Bellevue Centre
Suite 300 235 -15th Street
West Vancouver, BC V7T 2X1
Canada
604-921-1810
https://briacell.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

NameTitlePayExercisedYear Born
Dr. William V. Williams M.D.CEO, President & Director987.72kN/A1955
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.CFO & Corporate Secretary595.79kN/A1973
Dr. Miguel A. Lopez-Lago Ph.D.Chief Scientific Officer481.13kN/A1969
Dr. Giuseppe Del Priore M.D., M.P.H., MPHChief Medical Officer726.69kN/A1962
Dr. Charles Louis Wiseman FACP, M.D.Founder, Principal Research Advisor & Member of Scientific Advisory Board324.31kN/A1946
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Corporate Governance

BriaCell Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.